Symbols

VRNA(Delisted)

Verona Pharma·NASDAQ

--(--)

Signals Analysis

Bullish signal 0

Bearish signal 1

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About VRNA

Verona Pharma Plc

A clinical-stage biopharmaceutical company focused on respiratory diseases

Industry

Established Date

02/24/2005

Listing Date

04/27/2017

Exchange

NASDAQ Stock Exchange

Full-time Employees

209

Fiscal Year Ends

12-31

Website

www.veronapharma.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

3 More London Riverside, London SE1 2RE , United Kingdom

Business

Introduction

Verona Pharma PLC was incorporated under the laws of England and Wales on 24 February 2005 under the name Isis Resources plc. In September 2006, the company acquired Rhinopharma Limited, a private company incorporated in Canada, and changed its name to Verona Pharma PLC. The Company is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for respiratory diseases with significant unmet medical needs.

Earnings Call

Q1/2025

Estimate EPS-0.03

Actual EPS-0.16

Estimate Revenue55.32M

Actual Revenue76.26M

Navigating Contradictions: Sales Growth and Gross-to-Net Expectations in Recent Earnings Calls

May 02,2025 12:49·
Earnings Decrypt

Company Financials

EPS

VRNA has released its 2025 Q2 earnings. EPS was reported at 0.14, versus the expected 0.1, beating expectations. The chart below visualizes how VRNA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

VRNA has released its 2025 Q2 earnings report, with revenue of 103.14M, reflecting a YoY change of NaN%, and net profit of 11.92M, showing a YoY change of 116.83%. The Sankey diagram below clearly presents VRNA's revenue sources and cost distribution.